Nasopharyngeal Carcinoma
Conditions
Keywords
Nasopharyngeal Carcinoma, SHR-1701, Famitinib
Brief summary
This is an open label, multi-center, phase I/II study to evaluate the efficacy and safety of SHR-1701 in combination with famitinib in subjects with recurrent/metastatic nasopharyngeal carcinoma(R/M NPC).
Interventions
DRUGSHR-1701
Intravenous (IV) on Day 1 of each cycle
DRUGFamitinib
Famitinib, po, qd
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed Recurrent/Metastatic Nasopharyngeal Carcinoma * Subjects failure after platinum-based chemotherapy and anti-PD-1/PD-L1 antibody therapy; * Able and willing to provide signed informed consent form, and able to comply with all procedures. * Life expectancy \>= 12 weeks as judged by the Investigator. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at trial entry. * Disease must be measurable with at least 1 uni dimensional measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. * Adequate hematological, hepatic and renal function as defined in the protocol Other protocol-defined inclusion criteria could apply
Exclusion criteria
* Anticancer treatment within 28 days before the first dose of study drug. * Major surgery within 28 days before start of trial treatment. * Systemic therapy with immunosuppressive agents within 7 days prior to the first dose of study drug; or use any investigational drug within 28 days before the start of trial treatment. * With any active autoimmune disease or history of autoimmune disease. * With active central nervous system (CNS) metastases causing clinical symptoms or requiring therapeutic intervention. * History of immunodeficiency including seropositive for human immunodeficiency virus (HIV), or other acquired or congenital immunedeficient disease, or any active systemic viral infection requiring therapy. * Previous malignant disease (other than the target malignancy to be investigated in the trial) within the last 2 years. Subjects with history of cervical carcinoma in situ, superficial or non-invasive bladder cancer or basal cell or squamous cell cancer in situ previously treated with curative intent are NOT excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR | up to approximately 2 years (anticipated) | ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: at least 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| DoR | up to approximately 2 years (anticipated) | Duration of Response per RECIST 1.1 |
| DCR | up to approximately 2 years (anticipated) | DCR is defined as the percentage of participants in the analysis population who have a CR, PR or SD per RECIST 1.1. |
| PFS | up to approximately 2 years (anticipated) | PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurs first. |
| OS | up to approximately 2 years (anticipated) | Overall Survival is defined as the time from registration to death due to any cause, or censored at date last known alive. OS will be measured by the Method of Kaplan and Meier. |
| AEs | up to approximately 2 years (anticipated) | Number of participants with adverse events as assessed by CTCAE v5.0 |
Countries
China
Contacts
Primary ContactQing Yang, MD
Backup ContactYanbo Liu, MB
Outcome results
None listed